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Sinary The photonecrotic effectveness of a morpholinothiolporphyn derived from haematoporphyrm
was measured in an animal model of cerebral glioma. The dose administered was 20mgkg-' and the laser
dose varied from 0 to 200J cm2. The tumour nerosis was at least as good as that of HpD, and this
therapeutic response may be attributed to the targeting of specific 'photopotent' subcellular sites.
Photodynamic therapy (PDT) is a bimodal therapy compris-
ing the enhanced uptake and retention of particular
sensitisers by tumour tissue followed by light-induced de-
struction (Lipson et al., 1961; Gomer & Dougherty, 1979).
Certain tumours offer great suitability to be treated success-
fully using PDT in conjunction with surgery. Brain tumours
are especially suited to PDT sine conventional treatments
fail (Kaye & Hill, 1992) as a result of local recurrence of the
tumour, suggesting that a therapy which targets the non-
resectable tumour margin and invasive nests of tumour cells
is appropriate.
One major reason for the effectiveness ofPDT is the extent
of localisation that can be achieved within intracranial
tumours, owing mainly to the breakdown ofthe blood-brain
barrier within tumour regions and the retention of an intact
blood-brain barrier in normal brain (Kaye et al., 1985).
Tumour death is proposed to occur primarily through
damage generated by the production of singlet oxygen and,
since the reactive species is restricted by its short lifetime to a
distance of 0.1 gm (Moan et al., 1979), organelle-targeting
photosensitisers may therefore increase the efficacy of
PDT.
At present, haematoporphyrin derivative (HpD) and the
more hydrophobic and purified form, Photofrin II, are the
experimentally and clinically most frequently used photosen-
sitisers (Kaye et al., 1988). HpD phototherapy has produced
encouraging results (Kaye, 1989; Kaye & Hill 1992), but an
alternative photosensitiser is desirable as HpD is a poorly
defined mixture ofporphyrins (Dougherty, 1987). In order to
establish the optimal structural characterstics of photosen-
sitsers required for PDT, we recently synthesised and tested
a series of porphyrin analogues (Woodburn et al., 1922a-c).
From this series MTP [7,12-bis(l-(2-morpholinoethanethiol)
ethyl)-3,8,13,17-tetramethyl-21H,23H-porphyrin-2,18-dipro-
panoic acid, Figure 1] was selected as the compound which
exhibited the best prospects for a new photosensitiser with
selective tumour-brain lalisation and good in vitro
photodynamic esponse. We now present the results ofin vivo
PDT studies an intacrebral glioma model to describe
the tumour oeaoss induced by MTP and attribute the tumour
kill to the capacity of MTP to localise in lysosomes.
grown in RPMI-1640 medium (Commonwealth Serum
Laboratories, Parkville, Australia) supplemented with 10%
fetal calf serum (Gibco, Helena Laboratories, Australia) and
maintained at 37C in 5% carbon dioxide.
Intracranial implantations
Forty adult Wistar rats (either sex) weighing between 200
and 400 g were obtained from the animal colony in the
Department of Surgery (Melbourne University, Australia).
The method for establishing intracranial tumours was that
developed by Kaye et al. (1985).
Porphyrins
Haematoporphyrin derivative (HpD) was obtained from the
Pharmacy Department, Queen Elizabeth Hospital (Adelaide,
South Australia), and was the same preparation as used
clinically by Kaye (Hill et al., 1990) in the treatment of
human glioma. MTP was prepared from haematoporphyrin
(Roussel UCLAF, Sydney, Australa). The synthesis and
characterisation will be presented elsewhere. Purity was
>99% as established by analytcal high-performance liquid
chromatography (HPLC), and the structure was confirmed
by infrared, 'H and '3C nuclear magnetic resonance (NMR)
and electrospray mass spectrometry.
Photodyninic therapy
The rats were injected, intravenously via the femoral vein,
with either MTP or HpD (20mgkg-') 9 days post inocula-
tion of the C( glioma cells. Five animals were used for each
time point. PDT was performed on the rats 24 h after i.v.
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The C6 glioma cell line was obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells were
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Fugwe 1 Stucture of 7,12-bis(l-(2-morphoinoethanethiol)ethyl)-
3,8,13,17-tetramethyl-21H,23H-porphyrin-2,18-dipropanoic acid
(denoted here as MTP).
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injection of the porphyrin in a manner similar to that de-
scribed by Kaye et al. (1985), except that irradiation was
with light of 628 nm from a gold metal vapour laser (Quen-
tron, Adelaide, South Australia). The light was delivered
through a quartz fibre (600pm inner core diameter), which
was placed in an integrating sphere with attached power
meter. This enabled a calculation of the total energy
administered (Jcm-) to the craniotomy site. The fibre tip
was held at a distance of 3-4mm over the area of the
craniotomy so that emitted red light evenly covered the
exposed tumour.
The laser power at the fibre tip was kept at 1 W, and light
was delivered at a dose of 0, 50, 100 or 200J cm-2 (Kaye et
al., 1985). The surface ofthe brain was irrigated with isotonic
saline solution kept at room temperature during irradiation
so as to prevent thermal damag to tumour or normal tissue.
On completion ofirradiation a single layer of Surgicel (John-
son & Johnson, North Ryde, New South Wals, Austalia)
was used to cover the craniotomy site and the wound was
closed with clips.
The animals were sacrificed 5 days after PDT treatment.
The brains were removed, fixed in 10% formaldehyde, sec-
tioned through the area of irradiation and stained with
haematoxylin and eosin. The extent of cerebral necrosis was
measured on serial sections using a graticule micrometer
(Leitz, Wetzlar, Germany) as previously described by Kaye
and Morstyn (1987).
Resits
The in vivo model used produced intracranial tumours
greater than 5 mm in diameter in 90% of the animals at 21
days when C6 cells (105) were injected into the frontal lobe of
adult Wistar rats (Kaye et al., 1985). The porphyrin dose
(20mg kg-') and the laser doses (0, 50, 100 and 200Jcm-)
were chosen as Kaye and Morstyn (1987) had previously
shown that normal brain necrosis does not occur following
HpD sensitisation until doses greater than 20mg kg-' and
200J cm-2 are used.
MTP is an impressive tumour photosensitiser, and the
observed tumour necrosis compares favourably with HpD
(Table I). Like HpD, no photonecrosis was observed in
normal brain using these light doses. MTP produced similar
tumour kill at all light doses studied, and at a dose of
1OOJcm-2 the depth of tumour necrosis was 3.6mm com-
pared with 2.8 mm for HpD. At 200Jcm-2 extensive tumour
kill was observed with MTP, while almost complete kill was
observed with HpD.
The similar photosensitising effectiveness of MTP and HpD
observed in this study may be due to a variety of previously
studied factors (an increase in lipophiicity with decreasing
pH; facile in vitro dark cytotoxicity and potent phototoxicity
values; discrete subcellular localisation sites, and high localis-
ing propensity in tumour tissue compared with the surround-
ing normal brain tissue). Photosensitisers that exhibit an
increase oflipophilicity with decreasing pH have been shown
to be retained more in tumour tissue than those compounds
which exhibit other trends (Moan et al., 1987). Both MTP
and HpD exhibit increasing partition coefficients with
decreasing pH (Woodburn et al., 1992b).
Table I Extent ofphotonecrosis by MTP and HpDwith varying light
dose
MTP- depth of HpD - depth oftnour
Tiss Laserpower twmou necrosis necrosis
type (Jcm-2) (mm) (mm)
o 0 0 0
C6 0 0 0
0 50 0 0
C6 50 2.1±0.2 1.5±0.9
0 100 0 0
C6 100 3.6±0.3 2.8±1.0
0 200 0 0
C6 200 4.7±0.2 4.5±1.5
The depth of tumour kill in the Wsar rat C6 glioma model after
iradiation with the gold vapour laser 24 h after injection 20mg '
HpD(Kaye&Morstyn, 1987)orMTP. Fiveanimals wereusedforeach
data pomt The depth oftumour nerosis shown is the average ofsix
measurements (at each ofthree cross-cions ofthe tumour), and this
was arried out on all five aninmls. The error shown is the standard
deviation ofthe measurements.
Dark cytotoxicity and phototoxicity values for MTP and
HpD were determined in in vitro cultures of C6 glioma cells
(Woodburn et al., 1992a). The ID_v for HpD was 17.511M
and for MTP 90FM, where the ID_, is the dose required for
50% inhibition of colony survival in the dark. MTP was
more effective than HpD in mediating cell death in vitro. The
IT,, for HpD was 45 mi, and for MTP it was 12 mi, where
the IT,o is defined as the time required for 50% inhibition of
colony survival when exposed to red light at a level equiva-
lent to the ID,. MTP displayed a selective tumour localisa-
tion (Woodburn et al., 1992b) in the murine C6 glioma
model. The tumour uptake determined at 6 and 24 h post
injection was 10.2 and 6.2 gg-' respectively for HpD, and
11.7 and 7.2JAgg-I respcively for MTP. Since the site of
photosensibser localisation within the tumour mass is
thought also to represent the site of photodamage (Moan et
al., 1979), subceliular distribution studies provide some
indication of the relative effectiveness of a particular
photosensitser. MTP distibutes in the lysosomes of C6
glioma cells, while HpD displays diffuse cytoplasmic plus
perinuclear staining of the cells (Woodburn et al., 1991). In
vitro lysosomes offer a more effective photodynamic target
than diffuse sites within the cytoplasm. In vivo photosensitisa-
tion of lysosomes may result in organelie rupture with the
release ofhydrolytic enzymes which have the potential to kill
cells and surrounding tissue (Allison et al., 1966; von
Ardenne & Kruger, 1979).
The clinical effectiveness of PDT depends upon the deter-
mination of factors such as sensitiser and light, the dosage
administered, tumour uptake and tissue distribution of the
photosensitiser. In this study the photonecrotic effectiveness
of MTP was measured in the rat C6 intracerebral glioma
model. MTP, a pure compound that is less toxic than HpD
and has a good tumour localising capacity, was at least as
good as HpD in eliciting tumour death. Future design of
prospective photosensitisers for use in PDT can therefore be
based upon this chemically pure compound (in contrast to
the range of components in HpD) and offers the chance to
develop struture-activity relationships for this type of
photosensitiser that appears to target specific organelles.
Abbreviato MTP, (7,12-bis(1-(2-morpholinoethanethiol)ethyl)-
3,8,13,17-tetra-methyl-21H,23H-porphyrin-2,18-dipropanoic acid);
PDT, photodynamic therapy; HpD, haematoporphyrin derivative.
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